Bruker Announces Acquisition of Inscopix for Neuroscience Research
November 08 2022 - 7:00AM
Business Wire
Head-Mounted Miniscopes Expand Neural
Functional Imaging Capabilities
Bruker Corporation (Nasdaq: BRKR) today announced the
acquisition of Inscopix, Inc., a neuroscience pioneer and market
leader of miniaturized microscopes, known as miniscopes, for freely
moving animal brain imaging. Since its founding in 2011, Inscopix's
flagship miniscope systems have been deployed in over 600 research
institutions and biopharma companies worldwide, empowering
breakthroughs in fundamental neuroscience research and advancing
the understanding of mechanisms in neurological disorders. This
acquisition enhances Bruker’s strong reputation as a technology
leader for in-vivo brain functional imaging with Ultima multiphoton
microscopes at the cellular level and preclinical MRI systems at
the organismal level.
“We are very proud of how far Inscopix has come in 10 years,”
said Dr. Kunal Ghosh, Founder and CEO of Inscopix. “We’ve built an
end-to-end ecosystem for neuroscience research, from reagents and
streamlined workflow solutions to a full analysis pipeline. This
acquisition will accelerate our mission of enabling a better
understanding of the neural circuitry underpinning brain function
and behavior, and to assist the development of new and better
neurotherapeutics by our biopharma partners. As part of Bruker, we
can take the next step in technology and new platform development
for both academic and pharma customers.”
“Inscopix has created the head-mounted live-animal microscopy
segment as a pioneer in enabling neuroscience research. Adding
these products and services to our leading position in multiphoton
microscopy allows an even greater level of coordination for
scientific advancement,” added Dr. Mark R. Munch, Bruker NANO Group
President. “With our high-resolution multiphoton microscopy and
Inscopix’s free-moving head-mounted imaging, we can now offer a
broad range of capabilities for exploring neural network function
in animals. We look forward to seeing these synergies enable
innovative academic and preclinical research.”
Inscopix revenue in FY 2022 is anticipated to be approximately
$20-25 million. Bruker expects Inscopix to continue to grow
revenues with double digit annual growth rates. Financial details
of the transaction were not disclosed.
About Inscopix, Inc. Based in Mountain View, CA, Inscopix is a
private company founded in 2011 from Stanford University research
that led to the invention of the miniscope. The innovation at the
core of the Inscopix brain-mapping platform is the integration and
miniaturization of the benchtop fluorescence microscope into a
2-gram device that can be mounted onto the head of a freely
behaving animal to observe its brain activity. With over 1000
installations worldwide, these miniscopes are empowering advances
in neuroscience research and preclinical research for the
development of transformational therapeutics. Learn more at
www.inscopix.com.
About Bruker Corporation (Nasdaq: BRKR) Bruker is enabling
scientists to make breakthrough discoveries and develop new
applications that improve the quality of human life. Bruker’s
high-performance scientific instruments and high-value analytical
and diagnostic solutions enable scientists to explore life and
materials at molecular, cellular, and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
improved productivity, and customer success in life science
molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108005224/en/
Investors: Justin Ward Senior Director, Investor
Relations & Corporate Development T: +1 (978) 663-3660 x1479 E:
Investor.Relations@bruker.com Media: Stephen Hopkins Content
Marketing Manager T: +1 (520) 741-1044 x1022 E:
steve.hopkins@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024